Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Aerts

Showing results (71-80 of 360) with videos related to

Pageof 36
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|October 15, 2005
[From gene to disease; Gaucher disease]C E M Hollak, R G Boot, B J H M Poorthuis, et al.
Blood Cells, Molecules & Diseases|October 24, 2007
Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapyM Langeveld, M de Fost, J M F G Aerts, et al.
Handbook of Experimental Pharmacology|March 22, 2025
Activity-Based Profiling of Retaining Glycosidases in Disease Diagnosis and Their Application in Drug DiscoveryYevhenii Radchenko, Johannes M F G Aerts, Gideon J Davies, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 14, 2008
The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cellsNora Bijl, Saskia Scheij, Sander Houten, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 3, 2019
The relation between psychological profiles and quality of life in patients with lung cancerEveline van Montfort, Jolanda de Vries, Rita Arts, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 27, 2005
Home treatment for Fabry disease: practice guidelines based on 3 years experience in The NetherlandsGabor E Linthorst, Anouk C Vedder, Els E Ormel, et al.
Journal of Inherited Metabolic Disease|June 10, 2006
Substrate reduction therapy of glycosphingolipid storage disordersJohannes M F G Aerts, Carla E M Hollak, Rolf G Boot, et al.
International Journal of Molecular Sciences|December 28, 2018
Glycoprotein Non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in MacrophagesMartijn J C van der Lienden, Paulo Gaspar, Rolf Boot, et al.
American Journal of Human Genetics|December 10, 2002
Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNADaniël Blom, Dave Speijer, Gabor E Linthorst, et al.
Kidney International|October 2, 2004
Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and betaGabor E Linthorst, Carla E M Hollak, Wilma E Donker-Koopman, et al.
Pageof 36

Showing results (71-80 of 360) with videos related to

Sort By:
Pageof 36
Nederlands Tijdschrift Voor Geneeskunde|October 15, 2005
[From gene to disease; Gaucher disease]C E M Hollak, R G Boot, B J H M Poorthuis, et al.
Blood Cells, Molecules & Diseases|October 24, 2007
Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapyM Langeveld, M de Fost, J M F G Aerts, et al.
Handbook of Experimental Pharmacology|March 22, 2025
Activity-Based Profiling of Retaining Glycosidases in Disease Diagnosis and Their Application in Drug DiscoveryYevhenii Radchenko, Johannes M F G Aerts, Gideon J Davies, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 14, 2008
The glucosylceramide synthase inhibitor N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin induces sterol regulatory element-binding protein-regulated gene expression and cholesterol synthesis in HepG2 cellsNora Bijl, Saskia Scheij, Sander Houten, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 3, 2019
The relation between psychological profiles and quality of life in patients with lung cancerEveline van Montfort, Jolanda de Vries, Rita Arts, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 27, 2005
Home treatment for Fabry disease: practice guidelines based on 3 years experience in The NetherlandsGabor E Linthorst, Anouk C Vedder, Els E Ormel, et al.
Journal of Inherited Metabolic Disease|June 10, 2006
Substrate reduction therapy of glycosphingolipid storage disordersJohannes M F G Aerts, Carla E M Hollak, Rolf G Boot, et al.
International Journal of Molecular Sciences|December 28, 2018
Glycoprotein Non-Metastatic Protein B: An Emerging Biomarker for Lysosomal Dysfunction in MacrophagesMartijn J C van der Lienden, Paulo Gaspar, Rolf Boot, et al.
American Journal of Human Genetics|December 10, 2002
Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNADaniël Blom, Dave Speijer, Gabor E Linthorst, et al.
Kidney International|October 2, 2004
Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and betaGabor E Linthorst, Carla E M Hollak, Wilma E Donker-Koopman, et al.
Pageof 36